κ- and λ-Carrageenans from Marine Alga IChondrus armatus/I Exhibit Anticancer In Vitro Activity in Human Gastrointestinal Cancers Models

The carrageenans isolated from red algae demonstrated a variety of activities from antiviral and immunomodulatory to antitumor. The diverse structure and sulfation profile of carrageenans provide a great landscape for drug development. In this study, we isolated, purified and structurally characteri...

Full description

Saved in:
Bibliographic Details
Published in:Marine drugs 2022-11, Vol.20 (12)
Main Authors: Tiasto, Vladlena A, Goncharov, Nikolay V, Romanishin, Alexander O, Zhidkov, Maxim E, Khotimchenko, Yuri S
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Biological products
Care and treatment
Carrageenin
Chemical properties
Health aspects
Marine algae
Pharmaceutical research
Stomach cancer
Testing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The carrageenans isolated from red algae demonstrated a variety of activities from antiviral and immunomodulatory to antitumor. The diverse structure and sulfation profile of carrageenans provide a great landscape for drug development. In this study, we isolated, purified and structurally characterized κo- and λo- oligosaccharides from the marine algae Chondrus armatus. We further examined the tumor suppressive activity of both carrageenans in gastrointestinal cancer models. Thus, using MTT assay, we could demonstrate a pronounced antiproliferative effect of the carrageenans in KYSE-30 and FLO-1 as well as HCT-116 and RKO cell lines with IC[sub.50] 184~405 μg/mL, while both compounds were less active in non-cancer epithelial cells RPE-1. This effect was stipulated by the inhibition of cell cycle progression in the cancer cells. Specifically, flow cytometry revealed an S phase delay in FLO-1 and HCT-116 cells under κo-carrageenan treatment, while KYSE-30 demonstrated a pronounced G[sub.2] /M cell cycle delay. In line with this, western blotting revealed a reduction of cell cycle markers CDK2 and E2F2. Interestingly, κo-carrageenan inhibited cell cycle progression of RKO cells in G[sub.1] phase. Finally, isolated κo- and λo- carrageenans induced apoptosis on adenocarcinomas, specifically with high apoptosis induction in RKO cells. Overall, our data underline the potential of κo- and λo- carrageenans for colon and esophageal carcinoma drug development.
ISSN:1660-3397
1660-3397
DOI:10.3390/md20120741